© 2023 BioMarin. All rights reserved.

Investors & Media

BioMarin R&D Day

September 12, 2023

Webcast Replay Presentation

Stock Quote
Transforming Lives Through Genetic Discovery

We seek to make a big difference in genetic disorders. At BioMarin, through our unparalleled expertise in genetics and molecular biology, we will continue to develop targeted therapies that address the root cause of the conditions we seek to treat. Applying our knowledge to make a transformative impact is not just a calling, but an obligation to those who will benefit most.

Fast Facts

>$2 Billion

in 2022 FY Total Revenues

78 Countries

Commercial Footprint

World-class Capabilities

Manufacturing, R&D, Regulatory, and Commercial

"Core 4" Product Framework

Genetic, Targeted, Assessable, Transformational

Tuesday, September 12, 2023
1:25pm EDT
Tuesday, September 12, 2023
8:00am - 12:00pm EDT

All Events

Latest News
Sep 21, 2023

Label Expansion Decisions Expected from U.S. and European Regulatory Authorities in Q4 SAN RAFAEL, Calif., Sept. 21, 2023 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN), a global...

Sep 15, 2023

European Commission Approval Decision Expected Q4 2023 Opinion Based on Positive Results from Global Phase 2 and Ongoing Extension Study U.S. Food and Drug Administration PDUFA Target Action Date...

Sep 11, 2023

BioMarin Pharmaceutical Inc. (Nasdaq: BMRN), a global biotechnology company dedicated to transforming lives through genetic discovery, will update the investor community on the company's research...

All Press Releases

A commitment to corporate responsibility.

We are committed to conducting our operations and managing our products in a responsible manner and in accordance with applicable laws, rules, and regulations. We regularly review our operations to improve efficiency and reduce environmental impact where appropriate.


Learn More

We take on the biggest challenges in rare disease.

Each drug candidate we pursue is guided by a fundamental understanding of the genetics and underlying biology of the condition it will address.


Learn More


Our executive team is made up of tech leaders with diverse backgrounds and a singular focus.



Contact Us

Investor Relations

Media & Press

Email Alerts

Sign up for alerts to receive updates on company announcements, financial information and more!